In contrast, pioglitazone, a peroxisome proliferator-activated receptor gamma (PPARγ) agonist that is also used as a medication for T2D, has been shown to be effective in decreasing steatosis, NAS, and liver damage8. This evidence concerns the gene PPARG and neonatal abstinence syndrome.